Literature DB >> 19590186

Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.

Yun-Peng Hua1, Xiao-Yu Yin, Bao-Gang Peng, Shao-Qiang Li, Jia-Ming Lai, Hui-Zhen Liang, Li-Jian Liang.   

Abstract

BACKGROUND: Somatostatin receptors (SSTRs) belong to the family of G protein-coupled receptors. Exposure of G protein-coupled receptors to their agonists induces a rapid decrease in their initial response. The goal of this study is to investigate alteration in SSTR2 by the treatment of SSTR agonist octreotide (OCT) in hepatocellular carcinoma (HCC) and the resulting consequence.
METHODS: Morphology, proliferation and cell cycle of the human HCC cell line (Bel7402) were evaluated. Effect of OCT on HCC growth and development was assessed in vivo. SSTR2 expression was measured by RT-PCR and detected by immunohistochemistry.
RESULTS: Short-term OCT treatment on Bel7402 cells barely changed cell proliferation and morphology, and no apoptosis was induced. The SSTR2 protein level was markedly decreased on Bel7402 cells after exposure to OCT. However, the weight of the HCC xenograft was significantly lower in the OCT treatment group as compared with the control group. In the rat hepatocarcinogenesis model, the mortality and incidence of HCC in the OCT treatment group were remarkably less than those in the control group. Long-term OCT treatment led to increased levels of both SSTR2 mRNA and protein in hepatocytes and HCC cells.
CONCLUSION: Short-term OCT treatment could lead to SSTR2 desensitization, resulting in a reduced inhibitory effect on HCC by OCT. However, long-term OCT treatment effectively inhibited the development and growth of HCC probably via resensitization and upregulation of SSTR2. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590186     DOI: 10.1159/000227763

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

1.  The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma.

Authors:  N M Abdel-Hamid; O M Mohafez; M H Nazmy; A Farhan; K Thabet
Journal:  Environ Health Prev Med       Date:  2015-03-01       Impact factor: 3.674

2.  Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro.

Authors:  Yang Shen; Mulan Ren; Yuehua Shi; Yunxia Zhang; Yunlang Cai
Journal:  Exp Ther Med       Date:  2011-08-11       Impact factor: 2.447

3.  Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells.

Authors:  Nikos J Tsagarakis; Ioannis Drygiannakis; Antonis G Batistakis; George Kolios; Elias A Kouroumalis
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

4.  Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma.

Authors:  N M Abdel-Hamid; O M Mohafez; S Zakaria; K Thabet
Journal:  Tumour Biol       Date:  2013-10-26

Review 5.  Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.

Authors:  Saad Shaaban; Amr Negm; Elsayed E Ibrahim; Ahmed A Elrazak
Journal:  Oncol Rev       Date:  2014-05-28

6.  Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.

Authors:  Daniel Kaemmerer; Robin Schindler; Franziska Mußbach; Uta Dahmen; Annelore Altendorf-Hofmann; Olaf Dirsch; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

Review 7.  Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma.

Authors:  Argyrios Periferakis; Georgios Tsigas; Aristodemos-Theodoros Periferakis; Ioana Anca Badarau; Andreea-Elena Scheau; Mircea Tampa; Simona Roxana Georgescu; Andreea Cristiana Didilescu; Cristian Scheau; Constantin Caruntu
Journal:  Anal Cell Pathol (Amst)       Date:  2021-11-27       Impact factor: 2.916

8.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07

Review 9.  The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.

Authors:  Claudia Pivonello; Maria Cristina De Martino; Mariarosaria Negri; Gaia Cuomo; Federica Cariati; Francesco Izzo; Annamaria Colao; Rosario Pivonello
Journal:  Infect Agent Cancer       Date:  2014-08-20       Impact factor: 2.965

10.  Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection.

Authors:  Fei Ji; Zhi-Heng Zhang; Yi Zhang; Shun-Li Shen; Qing-Hua Cao; Long-Juan Zhang; Shao-Qiang Li; Bao-Gang Peng; Li-Jian Liang; Yun-Peng Hua
Journal:  BMC Cancer       Date:  2018-04-24       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.